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Introduction
Introduction
In October of 2017, the United States Department of Health and Human
Services declared a national public health emergency because of the
country’s opioid crisis. Opioid abuse has become a daunting public health
problem across the nation, and especially in the Philadelphia region. There
may be as many as 70,000 heroin users in the Philadelphia area along with
50,000 people that have misused prescription painkillers. In 2017, the
number of deaths caused by drug overdoses in Philadelphia were four
times greater than the number of deaths by homicide. Overall, the opioid
crisis costs the city an estimated $26 million a year or more. Combating
this problem has proven to be a challenge for health officials, and it is
imperative that measures are taken to decrease morbidity and mortality
related to opioid drug abuse and decrease healthcare costs. The Task Force
to Combat the Opioid Epidemic, created by Philadelphia mayor James
Kenney, produced a list of possible solutions that included implementing
a Comprehensive User Engagement Site (CUES) that would provide
medical resources and assistance for opioid users. This facility would allow
people who inject drugs (PWID) to do so under the supervision of trained
healthcare professionals. PWID would have access to clean needles,
overdose medications, patient education, and opportunities for recovery.
A similar safe injection facility (SIF) has been operating in Vancouver for
many years, and has had success in addressing both the costs and
complications associated with opioid abuse in Canada. This study analyzed
the clinical, ethical, and economic considerations associated with a
Methods
potential CUES site in Philadelphia,
using the Vancouver SIF as a model for
comparison.

Methods
 A review of the literature was conducted using PubMed, EMBASE, and
various public data sources. Search keywords related to the history and
efficacy of safe injection facilities (SIFs), their implementation to
Philadelphia, and other related terms were used.
 Semi-structured discussion sessions were conducted among members of
the Institute of Clinical Bioethics at Saint Joseph’s University, resident
physicians at Mercy Health System, and medical students at the
Philadelphia College of Osteopathic Medicine (PCOM). Topics of
discussion included the risks, benefits, and ethics involved in initiating a
CUES in Philadelphia, with research regarding past SIFs being uses as a
comparative model
 Each team conducted independent reviews of different aspects
regarding a proposed SIF in Philadelphia and presented their findings
back to the group.
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The Reality In Philadelphia:
2016: 907 deaths were documented to be caused by drug overdoses
 Of those, 80% were attributed to Opioids
2017: 1217 unintentional drug overdose deaths occurred in Philadelphia
 Fatal drug overdoses increased by 34% compared to 2016
 Opioids were found in 88% of drug deaths in 2017, up from 80% in 2016



935 Cases of secondary conditions
arose from Needle Sharing
Predicted that there are 4X as
many deaths from Overdose
compared to homicides

Figure 1.
Philadelphia Dept. of Public Health (2017)

Insite: Canada’s First Legally sanctioned Supervised Injection Facility
2003-Present:
 Insite has served as a scientific pilot and has resulted in :
 Reduction in public disorder (figure 2)
 Reduction in infectious disease transmission
 Reduction in incidence of drug overdose
 Increased participation in external treatment programs
 Did NOT result in an increase in Crime
 Overall Cost effective
 There have been 48,798 clinical treatment visits
 6,440 overdose interventions, and 0 deaths.

Figure 2: 6 weeks before and 12 weeks after
facility opened. Dotted line represents opening
of facility. Wood et al. (2004)

The Estimated Impact on Philadelphia:
Medical Analysis - Each year a CUES that saw 2000 patients would lead to an estimated
prevention of:
 3 to 48 cases of HIV infections annually
 15 to 213 cases of Hepatitis C annually
 24 to 76 overdose related deaths
Economic Analysis- Estimate of the impact of a hypothetical CUES in Philadelphia
 Reduction in costs related to hospitalizations for Skin and Soft tissue infections
were estimated to be $1.5 – $1.9 Million annually.
 Total value of overdose deaths averted: $12.5 to $74.8 Million annually
 Estimated Impact on Healthcare costs annually:
 A reduction in ambulance costs by $123,776 per year
 Annual savings of $280,683 due to a reduction in in hospital emergency
department utilization
 Annual savings of $271,971 on hospital costs due to reduced hospitalizations
for those who overdose
Ethical Analysis - revealed that safe injection is ethically permissible given the primary
intent is to limit the user’s exposure to harm.
 Reviewing existing evidence on Supervised Injection facilities and local data we
estimate the following harm reduction impact:
 Serves as an access point for drug and alcohol treatment
 Reduced incidence of disease transmission as well as drug overdose

Due to the effectiveness of Insite in Vancouver, our research seeks to
consider Comprehensive User Engagement Sites (CUES) as a viable option
in response to the growing Opioid Crisis in Philadelphia. As an extension of
the framework provided by Insite, the CUES model would offer additional
resources such as:
 Wound Care: It has been estimated that the annual savings of a CUES
skin and soft tissue service could save between $1.5-$1.8 million
annually. The integration of a wound care service with medical
education provides an opportunity for students to gain practical
experience, while witnessing first-hand the effects of opioid usage
within marginalized populations.
 Needle Exchange Program: between 1999 and 2014 the needle
exchange program reduced the number of HIV transmission cases
related to needle sharing from 46% in 1992 to 5.4% in 2014.
 Naloxone (Narcan®) distribution: The use of Narcan can further reduce
the current Philadelphia healthcare cost of $92,408 per hospitalization
with an average length of stay of 7-10 days attributed to overdose.
Applying the results from Vancouver’s Insite to a Philadelphia
Comprehensive User Engagement Site, the facility has the potential to be
highly successful. Experts from Insite project that a facility in Philadelphia
could lead to between 3 and 48 averted cases of HIV infection annually, 15
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to 213 averted cases of Hepatitis C cases annually, and prevent 24 to 76
overdose related deaths annually.
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